6110-36-7

Basic information

• Product Name: ethyl 4-methoxy-6-methylsalicylate
• Synonyms: ethyl 4-methoxy-6-methylsalicylate;2-hydroxy-4-methoxy-6-methyl-benzoic acid ethyl ester;Benzoic acid, 2-hydroxy-4-methoxy-6-methyl-, ethyl ester;Einecs 228-073-6;Ethyl 2-hydroxy-4-methoxy-6-methylbenzoate
• CAS NO: 6110-36-7
• Molecular Formula: C₁₁H₁₄O₄
• Molecular Weight: 210.22646
• EINECS: 228-073-6
• Mol File: 6110-36-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 87 °C
• Boiling Point: 317.3°Cat760mmHg
• Flash Point: 119.3°C
• Appearance: /
• Density: 1.151g/cm³
• Vapor Pressure: 0.000208mmHg at 25°C
• Refractive Index: 1.526
• PKA: 9.66±0.15(Predicted)
• CAS DataBase Reference: ethyl 4-methoxy-6-methylsalicylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-methoxy-6-methylsalicylate(6110-36-7)
• EPA Substance Registry System: ethyl 4-methoxy-6-methylsalicylate(6110-36-7)

Safety Data

• Hazardous Substances Data: 6110-36-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H14O4/c1-4-15-11(13)10-7(2)5-8(14-3)6-9(10)12/h5-6,12H,4H2,1-3H3

Upstream product

• 186581-53-3 diazomethane 
• 2524-37-0 ethyl orselinate 
• 64-17-5 ethanol 
• 570-10-5 2-hydroxy-4-methoxy-6-methylbenzoic acid 
• 75-03-6 ethyl iodide 
• 13321-73-8 2-bromo-1,5-dimethoxy-3-methylbenzene 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 55018-89-8 2,4-dimethoxy-6-methylbenzoyl chloride 
• 3686-57-5 2,4-dimethoxy-6-methylbenzoic acid 
• 92120-72-4 ethyl 2,4-dimethoxy-6-trimethylsilylmethylbenzoate 
• 21855-46-9 ethyl 3,5-dibromo-2,4-dihydroxy-6-methyl benzoate 
• 74-88-4 methyl iodide 
• 57749-86-7 ethyl 2,4-dimethoxy-6-methylbenzoate 

Downstream Products

• 111699-64-0 ethyl 2-benzyloxy-4-methoxy-6-methylbenzoate 
• 133363-14-1 ethyl 4-methoxy-2-(methoxymethoxy)-6-methylbenzoate 
• 104783-89-3 2'-hydroxy-4'-methoxy-6'-methyl-2-(methylsulfinyl)acetophenone 
• 133363-17-4 1-Benzyloxy-3-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-methoxy-8-methoxymethoxy-naphthalene-2-carbaldehyde 
• 133363-16-3 {1-Benzyloxy-3-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-methoxy-8-methoxymethoxy-naphthalen-2-yl}-methanol 
• 133363-18-5 1-Benzyloxy-5-bromo-3-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-6-methoxy-8-methoxymethoxy-naphthalene-2-carbaldehyde 
• 120461-92-9 calphostin A 
• 133363-23-2 [(R)-2-(4-Benzyloxy-8-bromo-3,7-dimethoxy-5-methoxymethoxy-naphthalen-2-yl)-1-methyl-ethoxy]-tert-butyl-diphenyl-silane 
• 133363-19-6 [(S)-2-(4-Benzyloxy-8-bromo-3,7-dimethoxy-5-methoxymethoxy-naphthalen-2-yl)-1-methyl-ethoxy]-tert-butyl-diphenyl-silane 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(R)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(R)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 

Relevant articles and documents

Stereoselective synthesis of resorcylic acid lactone Cochliomycin B

The total synthesis of 14-membered resorcylic acid lactone, Cochliomycin B has prescribed, in a convergent manner, from readily available starting materials, D-galactose, L-aspartic acid and ethyl acetoacetate. The key reactions involved in the synthesis are Julia-Kocienski olefination, E-selective Horner-Wadsworth-Emmons olefination and intramolecular lactonization.

Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin- 5(9bH)-ones as 5-HT2C receptor agonists

A series of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones is described, several examples of which exhibit potent 5-HT2C agonism with excellent selectivity over the closely related 5-HT2A and 5-HT2B receptors. Compounds such as 38 and 44 were shown to be effective in reducing food intake in an acute rat feeding model.

Pyrrolo(oxo)isoquinolines as 5HT ligands

The present application describes compounds according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I or pharmaceutically acceptable salt forms thereof, wherein A, B, D, E, m, n, R3, R7, R8, R9, R10, R11 and X are described herein.